靶向2014-2015年北美高致病性禽流感暴发H5的重组火鸡疱疹病毒疫苗效力评价
研究评估了三种含不同插入片段、靶向2014-2015年北美高致病性禽流感暴发分离株血凝素基因的实验性重组火鸡疱疹病毒载体疫苗。白来航鸡1日龄接种、4周龄攻毒A/Turkey/Minnesota/12582/2015 H5N2,三种疫苗生存率分别为100%、45%和15%,最有效疫苗显著减少口腔和泄殖腔排毒并在攻毒前产生特异性抗体。
要点
- 三种实验性重组火鸡疱疹病毒载体疫苗对H5N2攻毒的生存率分别为100%、45%和15%。
- 最有效疫苗较其他所有组显著减少口腔和泄殖腔排毒,并在攻毒前产生特异性抗体。
- 需更多研究以充分确定对不同H5Nx高致病性病毒分离株的覆盖广度及母源抗体对保护和疫苗效力的可能影响。
核心结论
- 三种实验性疫苗中,最有效疫苗对H5N2攻毒提供100%生存并显著减少口腔和泄殖腔排毒,但需更多研究以充分确定对不同H5Nx高致病性病毒分离株的覆盖广度及母源抗体对保护和疫苗效力的可能影响。
研究设计与样本
- 研究评估了三种含不同插入片段的实验性重组火鸡疱疹病毒载体疫苗,白来航鸡1日龄接种、4周龄以A/Turkey/Minnesota/12582/2015 H5N2攻毒,分析生存、感染后2天和4天排毒及攻毒前和存活鸡的特异性抗体。
主要发现
- 三种实验性疫苗的生存率分别为100%、45%和15%。
- 最有效疫苗较其他所有组显著减少口腔和泄殖腔排毒,并在攻毒前产生特异性抗体。
局限性
- 需更多研究以充分确定对不同H5Nx高致病性病毒分离株的覆盖广度,以及母源抗体对保护和疫苗效力的可能影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The outbreak of highly pathogenic avian influenza virus in North American poultry during 2014 and 2015 demonstrated the devastating effects of the disease and highlighted the need for effective emergency vaccine prevention and control strategies targeted at currently circulating strains. This study evaluated the efficacy of experimental recombinant turkey herpesvirus vector vaccines with three different inserts targeting the hemagglutinin gene of an isolate from the recent North American influenza outbreak. White leghorn chickens were vaccinated at one day of age and challenged with A/Turkey/Minnesota/12582/2015 H5N2 at 4 weeks of age. Birds were analyzed for survival, viral shedding at two and four days after infection, and specific antibody prior to challenge and from surviving birds. The three experimental vaccines demonstrated 100%, 45% and 15% survival with the most effective vaccine significantly reducing oral and cloacal viral shedding compared to all other groups and generated specific antibody prior to challenge with highly pathogenic avian influenza virus. More studies are needed using diverse H5Nx highly pathogenic virus isolates to fully determine the breadth of coverage against possible exposure strains, as well as possible impact of maternally derived antibody on protection and vaccine efficacy.
引用
- Balzli CL, Bertran K, Lee DH, et al. The efficacy of recombinant turkey herpesvirus vaccines targeting the H5 of highly pathogenic avian influenza virus from the 2014-2015 North American outbreak. Vaccine. 2017. PMID: 29180030. doi:10.1016/j.vaccine.2017.11.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。